Showing 281 - 300 results of 582 for search 'Liu Xie', query time: 0.06s Refine Results
  1. 281
  2. 282
  3. 283
  4. 284
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290
  11. 291
  12. 292
  13. 293

    PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study by He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y

    Published 2025-01-01
    “…Zhaoqian He,1– 3,* Hua Chen,1– 3,* Chen Liang,1– 3,* Xiang Tang,1– 3 Lingmin Jiang,1– 3 Feihu Xie,1– 3 Qi Liu,1– 3 Yun Zheng1– 3 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 3Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yun Zheng; Qi Liu, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China, Email zhengyun@sysucc.org.cn; liuqi9@sysucc.org.cnPurpose: To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab plus Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma.Patients and Methods: This real-world retrospective study enrolled 294 patients with unresectable HCC. …”
    Get full text
    Article
  14. 294
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299
  20. 300